HIV, HTLV AND DRUG ABUSE
HIV、HTLV 和药物滥用
基本信息
- 批准号:7562305
- 负责人:
- 金额:$ 7.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-05-01 至 2008-04-30
- 项目状态:已结题
- 来源:
- 关键词:AgeAmbulatory Care FacilitiesAnti-Retroviral AgentsCD4 Lymphocyte CountCategoriesCohort StudiesComputer Retrieval of Information on Scientific Projects DatabaseDetectionDiseaseDrug abuseEnrollmentEnzyme-Linked Immunosorbent AssayFundingGenderGenetic TranscriptionGrantHIVHIV-1HTLV-1 InfectionHighly Active Antiretroviral TherapyHuman T-lymphotropic virus 1Human T-lymphotropic virus 2IndividualInfectionInjection of therapeutic agentInstitutionMessenger RNANumbersPatientsPeripheral Blood Mononuclear CellPharmaceutical PreparationsRaceRangeReportingResearchResearch PersonnelResourcesSourceStagingT-Lymphocyte SubsetsTaxesUnited StatesUnited States National Institutes of HealthViral AntigensViral Load resultVirusWestern Blottingantiretroviral therapyburden of illnessmRNA Expression
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
HIV/HTLV co-infections occur frequently and in the range of 1-15% among HIV-1 infected individuals. The relationship between levels of HTLV-1/2 viral burden/disease, and effects of antiretroviral treatment, however, is unknown. HTLV1/2 and HIV ELISA positive co-infected individuals from the New Orleans HIV Outpatient Clinic (HOP), were identified and 72 patients enrolled and evaluated in the study, making this the largest co-infected patient cohort study in the United States. The variables analyzed included: HTLV-1/2 proviral load, HTLV-1/2 tax/rex mRNA expression, HIV viral load, HTLV-1/2 viral antigen detection in peripheral blood mononuclear cell (PBMC) cultures, T cell subsets, demographic variables (age, race, gender, reported use of injection drugs) and administration of highly active antiretroviral therapy (HAART). HTLV proviral load was dichotomized into d 20,000 and 20,000 categories for ease of comparison.
Among subjects with HIV/HTLV-1 co-infection, an HTLV-1/2 proviral copy number of 20,000 copies/106 PBMCs was significantly associated with a higher absolute CD4 cell count, HTLV-1 vs HTLV-2 western blot positivity, positive HTLV-1/2 PBMC culture , positive tax/rex mRNA, and an HIV viral load less than 10,000 copies/ml. There was no correlation between HTLV-1/2 proviral copy number or tax/rex RNA expression and administration of antiretroviral therapy. HTLV-1/2 proviral burden was significantly higher among HIV/HTLV-1 co-infected, versus HIV/HTLV-2 co-infected individuals. These results suggest that HTLV-1/2 viral burden in PBMCs has an impact on disease staging among HIV-infected individuals. HAART may be of limited value in controlling HTLV-1/2 virus expression in patients with HIV/HTLV-1/2 co-infections.
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
HIV/HTLV混合感染频繁发生,在HIV-1感染者中为1-15%。然而,HTLV-1/2病毒负担/疾病水平与抗逆转录病毒治疗效果之间的关系尚不清楚。来自新奥尔良HIV门诊诊所(HOP)的HTLV1/2和HIV ELISA阳性共同感染者被确定,72名患者参加了这项研究,使这项研究成为美国最大的联合感染患者队列研究。分析的变量包括:HTLV-1/2前病毒载量、HTLV-1/2Tax/rex基因表达、HIV病毒载量、外周血单个核细胞(PBMC)培养中HTLV-1/2病毒抗原检测、T细胞亚群、人口学变量(年龄、种族、性别、注射药物使用情况)和高效抗逆转录病毒治疗(HAART)的实施。为便于比较,HTLV前病毒负荷被分为D20000和20000两类。
在HIV/HTLV-1混合感染者中,HTLV-1/2前病毒拷贝数为20,000拷贝/106个PBMC的患者中,CD4细胞绝对数、HTLV-1与HTLV-2免疫印迹阳性、HTLV-1/2 PBMC培养阳性、Tax/rex mRNA阳性和HIV病毒载量<10,000拷贝/ml的患者显著相关,而HTLV-1/2前病毒拷贝数和Tax/rex RNA表达与抗逆转录病毒治疗的使用无关。HIV/HTLV-1混合感染者的HTLV-1/2前病毒负担显著高于HIV/HTLV-2混合感染者。这些结果表明,外周血单核细胞中HTLV-1/2病毒载量对HIV感染者的疾病分期有影响。HAART在控制HIV/HTLV-1/2混合感染患者HTLV-1/2病毒表达方面的价值可能有限。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
MARK A BEILKE其他文献
MARK A BEILKE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('MARK A BEILKE', 18)}}的其他基金
Immunomodulatory Function of Human T Cell Leukemia Virus Type 2 (HTLV-2)
人 T 细胞白血病病毒 2 型 (HTLV-2) 的免疫调节功能
- 批准号:
8259061 - 财政年份:2010
- 资助金额:
$ 7.16万 - 项目类别:
Immunomodulatory Function of Human T Cell Leukemia Virus Type 2 (HTLV-2)
人 T 细胞白血病病毒 2 型 (HTLV-2) 的免疫调节功能
- 批准号:
7925893 - 财政年份:2010
- 资助金额:
$ 7.16万 - 项目类别:
Immunomodulatory Function of Human T Cell Leukemia Virus Type 2 (HTLV-2)
人 T 细胞白血病病毒 2 型 (HTLV-2) 的免疫调节功能
- 批准号:
8195942 - 财政年份:2010
- 资助金额:
$ 7.16万 - 项目类别:
RETROVIRAL CO-INFECTIONS: HIV, HTLV AND DRUG ABUSE
逆转录病毒合并感染:HIV、HTLV 和药物滥用
- 批准号:
7376255 - 财政年份:2005
- 资助金额:
$ 7.16万 - 项目类别:
EXPERIMENTAL TRANSMISSION OF HTLV-I TO NONHUMAN PRIMATE
HTLV-I 向非人灵长类动物的实验传播
- 批准号:
7165019 - 财政年份:2005
- 资助金额:
$ 7.16万 - 项目类别:
RETROVIRAL CO-INFECTIONS: HIV, HTLV AND DRUG ABUSE
逆转录病毒合并感染:HIV、HTLV 和药物滥用
- 批准号:
7204000 - 财政年份:2004
- 资助金额:
$ 7.16万 - 项目类别:
EXPERIMENTAL TRANSMISSION OF HTLV-I TO NONHUMAN PRIMATE
HTLV-I 向非人灵长类动物的实验传播
- 批准号:
6970717 - 财政年份:2004
- 资助金额:
$ 7.16万 - 项目类别: